GlaxoSmithKline and Valeant Pharmaceuticals International announced today that, on 30 October, they filed a New Drug Application with the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMEA), for retigabine, used as adjunctive therapy to treat adult epilepsy patients with partial-onset seizures. Retigabine is not approved or licensed anywhere in the world.